


**Supplementary Table 1: mAb clone names, isotype and antigen specificities**

<b>Clone name</b>	<b>Specificity</b>	<b>Species</b>	<b>Isotype</b>	<b>References</b>
SMB19 <sup>1</sup>	Anti-GBSIb	Mouse, BALB/c	IgM, $\kappa$	[18]
SlaE7	Anti-GBSla	Mouse, BALB/c	IgM, $\kappa$	[49]
SIIF5C4	Anti-GBSII	Mouse, BALB/c	IgM, $\kappa$	[49]
SIIV18	Anti-GBSIII	Mouse, BALB/c	IgM, $\kappa$	[49]
SIdD2	Anti-desialylated GBSIb	Mouse, BALB/c	IgM, $\kappa$	[18]
A16	Anti- $\alpha$ -1,3 glucan	Mouse, BALB/c	IgM, $\lambda$	[50]
1-21	Anti- $\alpha$ -1,3 glucan	Mouse, BALB/c	IgM, $\lambda$	[50]
744	Anti- $\beta$ -1,3 glucan	Mouse, BALB/c	IgM, $\kappa$	[24]
SMBi26	Anti-SMB19	Rat	IgG1	


**Supplementary Table 1**

IgM antibodies were purified from supernatants of hybridomas grown in Gibco serum free RPMI1640 by affinity chromatography over RS3.1 mouse anti-IgM<sup>a</sup>-Sepharose affinity columns. IgG antibodies were purified by passage over Protein G-conjugated Sepharose beads. All antibodies were eluted with 0.1M Glycine-HCL in PBS, concentrated and buffer exchanged into PBS using Centricon Plus-70 centrifugal filters (Millipore). For quality control, purified antibodies were subjected to SDS-PAGE under reducing and non-reducing conditions to ensure correct molecular weight, as well as ELISA for antigen-binding. Purified antibody preparations were tested for endotoxin levels before injection by Limulus assay (Limulus Amebocyte Lysate Pyrogen, Lonza, Walkersville, MD) and were below the limits of detection.




**Supplementary Fig 1. SMB19 binds divergent species of *Aspergillus* and the protection observed in the i.v. model of I.A. is independent of neutrophil and T cell function, but requires complement activity.**

(A) Staining of *Aspergillus flavus* (upper) and *Aspergillus niger* (lower) with SMB19 (red) and calcifluor (chitin binding, green). (B) Corresponding SMB19 (green) binding or isotype control (SIBD2, red) detected by flow cytometry. (C) Survival of transiently neutropenic WT C57BL/6J mice passively administered 200  $\mu$ g SMB19 (green, n=15) or SIBD2 (red, n=14) i.p. 24 hours before i.v. infection with 2xLD<sub>50</sub> ( $2.5 \times 10^5$ ) A.f. conidia. (D) Survival of C3<sup>-/-</sup> mice passively transferred i.p. with 200  $\mu$ g SMB19 (green) or control isotype SIBD2 (red) immediately before i.v. infection with 2xLD<sub>50</sub> ( $2.5 \times 10^5$ ) A.f. (E) Survival of TCR $\beta$ / $\delta$ <sup>-/-</sup> mice passively administered SMB19 (green, n=11) or SIBD2 (red, n=12) i.p. immediately before i.v. infection with 2xLD<sub>50</sub> ( $2 \times 10^6$ ) A.f. conidia. Asterisks denote significant differences in average survival rate of SMB19 BCR Tg mice compared to WT C57BL/6J and J558 BCR Tg mice or mice passively transferred SMB19 compared to isotype control. Statistical significance was determined by log rank test \* = p<0.05, \*\* = p<0.01.



## Supplementary Fig 2

**SMB19 Id+ B cells in the peritoneal cavity are enriched in the B1b and B2 subsets, but are not enriched in any subset in the spleen.** (A) FACS analysis of SMB19 Id expression on B220+IgM+ cells in representative samples of the spleen, bone marrow, mesenteric lymph nodes, and peritoneal cavity using SMBi26, a rat anti-SMB19 anti-idiotype antibody. (B) FACS analysis of SMB19 Id+ enrichment in the immature fraction E, T1, T2, and T3 subsets of the spleen. (C) FACS analysis of SMB19 Id+ enrichment in the follicular, marginal zone, and pre-marginal zone mature B cell subsets of the spleen. (D) FACS analysis of SMB19 Id+ enrichment in the B1a, B1b, and B2 compartments of the peritoneal cavity. For panels A-D, open histograms represent SMB19 Id+ B cells in the SMB19 Tg mice and shaded histograms represent SMB19 Id+ B cells in WT littermate control mice. (E) Total number of SMB19 Id+ B cells in splenic B cell populations. (F) Total number of SMB19 Id+ B cells in peritoneal cavity B cell populations. (G) Spleen sections from SMB19 Tg mice were stained with anti-IgMa (green), anti-SMB19 Id (red), anti-Moma-1 (white), and anti-CD4+anti-CD8 (blue). (H) ELISA analysis of SMB19 (green) or SIaE7 (black) binding to SMB19 anti-idiotype mAb, SMBi26. Experiments were performed in triplicate twice with similar results.



**Supplementary Fig 3. SMB19 Tg mice have lower levels of pro-inflammatory cytokines in their sera after A.f. infection compared to control groups.** Luminex analysis of Th1 and Th2, and neutrophil proliferation-associated and survival, serum cytokine levels in SMB19 Tg (green), WT (black), J558 Tg (blue), and  $\mu$ MT (red) mice at various time points after i.v. infection with A.f. Data represent 2 independent experiments with similar results. Data was analyzed using a One-way ANOVA with a Tukey's post test  $*$ = p<0.05;  $**$ = p<0.01. Asterisks denote significant differences in cytokine levels between SMB19 Tg mice and control groups on day 4 post A.f. infection.